Navigation Links
BioSoteria CEO to Present at Drug Safety Conference
Date:11/18/2009

BioSoteria announced that its President and CEO Sally Van Doren, PharmD, will present at the 9th DIA Conference for Contemporary Pharmacovigilance and Risk Management Strategies, which takes place January 10-13, 2010, in Washington, DC. Dr. Van Doren will present on the topic of the Integrated Summary of Safety.

Emeryville, CA (PRWEB) November 18, 2009 -- BioSoteria, Inc., a drug safety service provider and training company, announced today that its President and Chief Executive Officer Sally Van Doren, PharmD, will present at the 9th Drug Information Association (DIA) Conference for Contemporary Pharmacovigilance and Risk Management Strategies. The meeting will take place January 10-13, 2010, in Washington, DC.

Dr. Van Doren will present on the topic of the Integrated Summary of Safety (ISS) during the session regarding Safety Reporting for Drugs and Biologics. Her talk will focus on the practical aspects of authoring the ISS, such as project planning, data pooling decisions, and integration points with the Common Technical Document and the product label.

"After authoring numerous safety analyses over the years, I have learned that the ISS is not as straight-forward as it appears in content requirements," said Dr. Van Doren. "I look forward to sharing my experience with this audience of drug safety professionals."

The DIA Conference for Contemporary Pharmacovigilance and Risk Management has become an important annual meeting for drug safety practitioners. The three-day program addresses regulatory activities and the complexities involved in maximizing the benefits and minimizing the risks of pharmaceuticals throughout all phases of development and marketed use. For more information, please visit the DIA website at www.diahome.org.

About Sally Van Doren, PharmD
Dr. Van Doren is the President, Chief Executive Officer and Founder of BioSoteria, the fastest-growing drug safety service provider and training company based on the West Coast. With more than twenty years of pharmaceutical industry experience, Dr. Van Doren has held leadership positions in drug safety and risk management, clinical development, and medical information services. She has been directly involved in numerous safety analyses for US and European product marketing applications and has advised many companies on a broad range of safety issues.

About BioSoteria, Inc.
BioSoteria is an innovative drug safety services and education provider to the biopharmaceutical industry. BioSoteria offers a wide range of consulting and operational services in clinical safety, postmarketing pharmacovigilance, and pharmaceutical risk management. To learn more about BioSoteria, please visit the company's website or call toll-free at 1-866-660-5553, extension 010.

###

Read the full story at http://www.prweb.com/releases/pharmacovigilance/conference/prweb3225234.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. BioSoteria Drug Safety Newsletter Reaches Milestone
2. BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification
3. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
4. Avicena Group to Present at Noble Financial Conference
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CEL-SCI to Present at the Noble Financial Conference
9. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
10. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
11. Strategic Diagnostics Updates Roth Conference Presentation Time
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
BioSoteria CEO to Present at Drug Safety Conference
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):